Biopharmaceutical News and Research

RSS

Early Detection of Off-Target Binding Could Improve Drug Safety

Integral Molecular, a pioneer in antibody discovery and characterization, has published new findings in the journal mAbs, revealing that up to one-third of antibody-based drugs exhibit nonspecific binding to unintended targets.

18 Sep 2024

One-Third of Antibody Drugs Show Unintended Target Binding

Integral Molecular, a leader in antibody discovery and characterization, has published new research in the journal mAbs, revealing that as many as one-third of antibody-based drugs exhibit nonspecific binding to unintended targets.

18 Sep 2024

Oxford University and Apollo Therapeutics Forge Collaboration to Accelerate Drug Discovery and Development

The University of Oxford (“Oxford”), one of the world’s leading research institutions and Apollo Therapeutics (“Apollo”), a portfolio biopharmaceutical company, announce the signing of a drug discovery and development collaboration aimed at translating breakthroughs made by biomedical researchers at Oxford.

29 Jul 2024

PhoreMost Introduces GlueSEEKER Platform for Discovery of Molecular Glue Degraders

PhoreMost Ltd., a leading UK biopharmaceutical company unlocking the next generation of drug targets, today announced the introduction of GlueSEEKER™. The new phenotypic screening platform expands the Company’s capabilities in this emerging therapeutic modality to support the systematic discovery and development of novel molecular glue degraders (MGDs) for targeted protein degradation (TPD).

From PhoreMost 22 May 2024

Sartorius Expands Collaboration with NVIDIA to Advance AI-Powered Drug Discovery

The life science group Sartorius is expanding its multidisciplinary collaboration with NVIDIA to help enable the development of new and better therapies, combining Sartorius’ in-depth knowledge of life sciences and bioprocessing with NVIDIA’s AI-powered computing platforms and software.

20 May 2024

Gyros Protein Technologies Launches Gyrolab Generic Rodent ADA Kit Reagents to Expedite Bioanalysis

Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction of Gyrolab Generic Rodent Anti-Drug Antibody (ADA) Kit Reagents for the detection of circulating immune complexes of human IgG with rodent anti-human IgG.

11 May 2024

Unraveling Lenacapavir's Impact on the HIV Life Cycle

A new anti-retroviral medication for the treatment of human immunodeficiency virus (HIV) infections was licensed by the US Food and Drug Administration and the European Union just over a year ago.

14 Feb 2024

Presage Biosciences and AstraZeneca Partner to Advance Immuno-Oncology Research for Head and Neck Cancer

Presage Biosciences, a pioneering translational oncology company whose mission is to use CIVO and spatial molecular profiling to understand the complexity of drug response in the tumor microenvironment (TME), has entered into an agreement with AstraZeneca, a global biopharmaceutical company.

1 Dec 2023

Clean Cells Doubles Capacity with Opening of New Production Suites

Clean Cells today announces the launch of operations in its new production suites, located in the new facility opened in January 2023.

27 Nov 2023

The Global Biopharma Community is Now Actively Partnering for BIO-Europe® 2023

The 29th annual BIO-Europe, the premier partnering conference for the global biopharmaceutical industry, is set to take place November 6–8, 2023, in the vibrant city of Munich, Germany.

27 Oct 2023

Study Uncovers Novel Genes Linked to Coronary Artery Calcification

An international team of scientists has identified nearly a dozen genes that contribute to calcium buildup in our coronary arteries that can lead to life-threatening coronary artery disease, a condition responsible for up to one in four deaths in the United States.

12 Oct 2023

PSG® Introduces New Biotech Brand

PSG®, a global pump, metering and dispensing-solution expert and an operating company within Dover Corporation, is proud to announce the creation and launch of its new PSG® Biotech brand.

3 May 2023

New Method for Improving Gene Therapy With Nanobubbles

Beyond vaccines, mRNA offers immense potential to fight disease, but targeting the genetic material to specific diseased cells is challenging-; requiring a new method.

12 Apr 2023

Newly developed toolkit uses small molecules to control the activity of synthetic RNA

The Okinawa Institute of Science and Technology, in collaboration with Astellas Pharma Inc., has developed a new toolkit that uses small molecules to control the activity of a piece of synthetic RNA, and ultimately regulate gene expression.

31 Mar 2023

Gyros Protein Technologies introduces new PurePep EasyClean services to accelerate development and manufacturing of peptide-based drugs

Gyros Protein Technologies AB today announced the launch of three service offerings to support development and manufacturing of peptide-based drugs.

From Gyros Protein Technologies AB 22 Mar 2023

Novel combination therapy shows promise in acute myeloid leukemia

Acute myeloid leukemia (AML) is an aggressive form of cancer that originates in the bone marrow, rapidly spreads to the blood and can quickly cause death if not treated promptly.

8 Feb 2023

Brooks Instrument announces new certifications available for its SLA Series of mass flow controllers

Brooks Instrument, a world leader in advanced flow, pressure and vapor delivery solutions, has released three new certifications available for its SLA Series and SLA Series Biotech mass flow controllers (MFCs) and meters, adding to its wide offering of product documentation.

From Brooks Instrument 3 Feb 2023

Gyros Protein Technologies adds Gyrolab® Biomarker Kits to expand range of ready-to-use kits and reagents

Gyros Protein Technologies AB today introduced Gyrolab® Human Cytokine Kit Reagents, the first in a range of new biomarker kits.

From Gyros Protein Technologies AB 30 Nov 2022

Fujifilm Invests $188 Million in New Cell Culture Media Manufacturing Facility

FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced a $188 million investment to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, USA.

From FUJIFILM Corporation 22 Nov 2022

New drug to tackle complex cases of UTI

A new drug combination has been shown to be more successful, especially against persistent, drug-resistant infections, according to an international study conducted by a Rutgers Researcher comparing new and older therapies for complex urinary tract infections.

From Rutgers University 28 Oct 2022